This page shows the latest Cablivi news and features for those working in and with pharma, biotech and healthcare.
atopic dermatitis and asthma therapy Dupixent (dupilumab) and Ablynx’ rare blood disorder product Cablivi (caplacizumab).
Alprolix – and the takeover of Belgian biotech Ablynx last year to claim rights to acquired thrombotic thrombocytopenic purpura (aTTP) therapy Cablivi (caplacizumab).
US approval of Cablivi adds to good news. Sanofi has put a long run of decline caused by patent losses in its rear view mirror, with rare disease unit Genzyme and ... from Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura (aTTP),
Analysts at Jefferies have suggested that Cablivi could be a game-changer in aTTP treatment and generate sales of up to $500m a year. ... Cablivi works by neutralising the blood glycoprotein von Willebrand factor (vWF), which is involved in blood clotting
Key developments for the company this year include the market development of Cablivi, which is approved in the EU and awaiting a final FDA nod, as well as the expected approval
dermatitis therapy Dupixent (dupilumab), checkpoint inhibitor Libtayo (cemiplimab) for cutaneous squamous cell carcinoma (CSCC) and Cablivi(caplacizumab) for acquired thrombotic thrombocytopenic purpura.
More from news
Approximately 2 fully matching, plus 8 partially matching documents found.
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 950 experts delivering world-class...